The combination of yondelis and cisplatin is synergistic against human tumor xenografts

European Journal of Cancer

Volumn 39, Issue 13, 2003, Pages 1920-1926

  D'Incalci, M ^a,d   Colombo, T ^a   Ubezio, P ^a   Nicoletti, I ^b   Giavazzi, R ^b,d   Erba, E ^a   Ferrarese, L ^a   Meco, D ^c   Riccardi, R ^c   Sessa, C ^d   Cavallini, E ^a   Jimeno, J ^e   Faircloth, G T ^f  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d SENDO   (Italy)

^e PHARMAMAR S A   (Spain)

^f PharmaMar USA Inc   (United States)

Author keywords

Cisplatin; Combination; ET 743; Marine natural products; Tumour xenografts

Indexed keywords

CISPLATIN; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; ISOQUINOLINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HEAD CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MALE; MELANOMA CELL; MOUSE; NECK CANCER; NEUROBLASTOMA CELL; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; EVALUATION; OVARY TUMOR; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DIOXOLES; DRUG SYNERGISM; FEMALE; HUMANS; ISOQUINOLINES; MICE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; RHABDOMYOSARCOMA; TETRAHYDROISOQUINOLINES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0142089888     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00490-8     Document Type: Article

References (30)

1. Rinehart K.L., Holt T.G., Fregeau N.L.et al. Ecteinascidins 729, 743, 745, 759A, 759B, and 770. potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinate J. Org. Chem. 55:1990;4512-4515.
2. Guan Y., Sakai R., Rinehart K.L., Wang A.H.J. Molecular and crystal structures of ecteinascidins. potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinate J. Biomol. Struct. Dyn. 10:1993;793-818.
3. Jimeno J.M., Faircloth G., Cameron L.et al. Progress in the acquisition of new marine-derived anticancer compounds. development of ecteinascidin-743 (ET-743) Drugs Future. 21:1996;1155-1165.
4. Valoti G., Nicoletti M.I., Pellegrino A.et al. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin. Cancer Res. 4:1998;1977-1983.
5. Hendriks H.R., Fiebig H.H., Giavazzi R., Langdon S.P., Jimeno J.M., Faircloth G.T. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann. Oncol. 10:1999;1233-1240.
6. Ghielmini M., Colli E., Erba E.et al. In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743). Ann. Oncol. 9:1998;989-993.
7. Izbicka E., Lawrence R., Raymond E.et al. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann. Oncol. 9:1998;981-987.
8. Li W.W., Takahashi N., Jhanwar S., Cordon-Cardo C.et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents. identification of ecteinascidin-743 as a potent cytotoxic agent Clin. Cancer Res. 7:2001;2908-2911.
9. Taamma A., Misset J.L., Riofrio M.et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J. Clin. Oncol. 19:2001;1256-1265.
10. Delaloge S., Yovine A., Taamma A.et al. Ecteinascidin-743. a marine-derived compound in advanced, pretreated sarcoma patients - preliminary evidence of activity J. Clin. Oncol. 19:2001;1248-1255.
11. Demetri G.D. ET-743. the US experience in sarcomas of soft tissues Anticancer Drugs. 13(Suppl. 1):2002;S7-S9.
12. Brain E.G. Safety and efficacy of ET-743. the French experience Anticancer Drugs. 13(Suppl. 1):2002;S11-S14.
13. D'Incalci M., Erba E., Damia G.et al. Unique features of the mode of action of ET-743. Oncologist. 7:2002;210-216.
14. Zwelling L.A., Anderson T., Kohn K.W. DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res. 39:1979;365-369.
15. Plooy A.C., van Dijk M., Lohman P.H. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Res. 44:1984;2043-2051.
16. Cohen S.M., Lippard S.J. Cisplatin. from DNA damage to cancer chemotherapy Prog. Nucleic. Acid. Res. Mol. Biol. 67:2001;93-130.
17. Pommier Y., Kohlhagen G., Bailly C., Waring M., Mazumder A., Kohn K.W. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the caribbean tunicate Ecteinascidia turbinate. Biochemistry. 35:1996;13303-13309.
18. Fink D., Zheng H., Nebel S.et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 57:1997;1841-1845.
19. Damia G., Silvestri S., Carrassa L.et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int. J. Cancer. 92:2001;583-588.
20. Erba E., Bergamaschi D., Bassano L.et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur. J. Cancer. 37:2001;97-105.
21. Takebayashi Y., Pourquier P., Zimonjic D.B.et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med. 7:2001;961-966.
22. Zewail-Foote M., Li V.S., Kohn H., Bearss D., Guzman M., Hurley L.H. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem. Biol. 8:2001;1033-1049.
23. Berenbaum M.C. The expected effect of a combination of agents. the general solution J. Theor. Biol. 114:1985;413-431.
24. Meco D, Colombo T, Ubezio P, et al. Effective combination of ET-743 and doxorubicin in sarcoma. Preclinical studies. Cancer Chemother Pharmacol [in press].
25. Masazza G., Lucchini V., Tomasoni A.et al. Malignant behavior and resistance to cisplatin of human ovarian carcinoma xenografts established from the same patient at different stages of the disease. Cancer Res. 51:1991;6358-6362.
26. Belotti D., Rieppi M., Nicoletti M.I.et al. Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. Clin. Cancer Res. 2:1996;1725-1730.
27. Nicoletti M.I., Lucchini V., Massazza G., Abbott B.J., D'Incalci M., Giavazzi R. Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice. Ann. Oncol. 4:1993;151-155.
28. Villalona-Calero M.A., Eckhardt S.G., Weiss G.et al. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily ×5 schedule in patients with solid malignancies. Clin. Cancer Res. 8:2002;75-85.
29. Rozencweig M., von Hoff D.D., Slavik M., Muggia F.M. Cis- diamminedichloroplatinum (II). A new anticancer drug. Ann. Intern. Med. 86:1977;803-812.
30. Sessa C., Colombo N., Bauer J.et al. Phase II study of salvage ET-743 given as 3-hr infusion in ovarian cancer (OC) patients. Ann. Oncol. 13(Suppl. 5):2002;109. [abstr].